1 / 38

FDG and its intended regulation by FDA in the USA: Points to Ponder

FDG and its intended regulation by FDA in the USA: Points to Ponder. Pradeep K. Garg, Ph.D. Director, PET Center Wake Forest University Health Sciences Winston Salem, NC; USA. STOP. PET Center. Three major domains: Radiopharmaceutical area: Chemist

declan
Download Presentation

FDG and its intended regulation by FDA in the USA: Points to Ponder

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. FDG and its intended regulation by FDA in the USA: Points to Ponder Pradeep K. Garg, Ph.D. Director, PET Center Wake Forest University Health Sciences Winston Salem, NC; USA STOP

  2. PET Center Three major domains: • Radiopharmaceutical area: Chemist • Imaging and data acquisition: Technologist • Reading scans and reporting: Physician STOP

  3. Radiopharmaceuticals Among several choices: FDG is widely accepted and dominates the market share STOP

  4. FDG regulations In US: • Expectation is to be compliant with cGMP • FDA requiring CMC • FDA differentiates between small and large manufacturers STOP

  5. cGMP current Good Manufacturing Practices Broad coverage, covers four major areas • Safety • Purity • Strength • Quality STOP

  6. CMC: The full form Chemistry, Manufacturing, and Controls Section STOP

  7. CMC CMC covers following points: • Drug product component and quantitative composition • Controls for components/raw materials • Reference standards • Manufacturing and testing facilities • Manufacture of drug substance • Manufacture of drug product STOP

  8. CMC (contn..) • Containers/closures • Controls for the finished dosage form • Analytical test procedures • Microbial Validation • Stability and Batch Records • Vials and outer packaging labels STOP

  9. A. Drug product component and quantitative composition • Drug substance: • Name/description: 2-Deoxy-2[18F]fluoro D-glucose, FDG. • Composition/mL: 10-20mCi at 9:30AM (EOS) • Composition/batch: 100-250mCi at 9:30AM (ESO) • Other ingredients: • Name/description: Sodium chloride injection, USP • Composition/mL: 1 mL • Composition/batch: 10-12 mL STOP

  10. B. Controls for components / raw materials • Organic substrates: • Target material (radioactive fluoride) • Other ingredients • Reagent STOP

  11. B.Controls for components and raw materials (contn) • Organic substrates: • Component name: 1,3,4,6-Tetrafluoro methanesulfonyl-D-mannopyranose (triflate) • Supplier: Name and address • Is this further purified: yes/no, if yes, how? • Acceptance specs: Tests and criteria • Appearance, Identity (nmr, ir), Purity (mp hplc). • COA • Identity test: test procedure and criteria in SOP • Storage condition: refrigerator, room temp, dry glove box,.. STOP

  12. B.Controls for components and raw materials (contn) • Target Material (O-18 water): • Name of Material • Manufacturer/supplier • Specifications • Identity test to release lot: as attachment • COA • Recycled: yes/no, if yes: • Procedure as attachment • Acceptance specs • *If F-18 purchased: supply all this info on it STOP

  13. B. Controls for components and raw materials (contn) • Reagent, solvents, gases, columns, and other auxiliary • Name • Supplier • Grade, quality, COA, and acceptance criteria The above info is needed for all materials used in the manufacturing STOP

  14. B. Controls for components and raw materials (contn) • Other ingredients (may not apply) • Name • Purpose • Manufacturer • Specifications STOP

  15. C. Reference standards Items: • 2-Fluoro-2deoxy-D-glucose • 2-Chloro-2deoxy-D-glucose • Kryptofix 222 On each of these items, supply: • Name of these standards • Suppliers info • Specifications, COA, acceptance criteria STOP

  16. D. Manufacturing and testing facilities • Name of PET facility and address • Contact person name • Contact person phone number STOP

  17. E. Manufacture of drug substance • Batch formula: Name, function, and quantities of each component • Triflate; used as a precursor, 10 mg • F-18 fluoride, radioisotope, 100-2000mCi • Radionuclide production • F-18 produced at site? Yes/no ; if yes: • Cyclotron • make and model, operating parameters, specifications on target body (volume, material, windows info, acceptance criteria on windows and body…) STOP

  18. E. Manufacture of drug substance (contn) • Synthesis and purification of drug • Synthesis and purification equipment • Description of equipment, its components, acceptance criteria, flow diagram: an attachment • Synth and purifi. Unit: make and model • Synthesis and purification operation Step wise description, amount of reagents, solvents, acceptable yields: an attachment • In process control Number of azeotropic evaps, temp for heating precursor, delivery rates, pressure for air and gases, hydrolysis temp, time for each steps, etc: a master production and control record section STOP

  19. E. Manufacture of drug substance (contn) • Post synthesis procedures: • Set up of synthesis units, cartridges • Cleaning and purging procedures • Provided as an attachment STOP

  20. F. Manufacture of drug products • Production operation General procedures provided as an attachment Master production and traceable control records provided as an attachment • Reprocessing of drug product • Yes/no, if yes, circumstances (Attachment) • Packaging and labeling • Detail descriptions as an attachment STOP

  21. G. Containers and closures • Using USP Type 1 glass, grey butyl stopper, and aluminum crimp seal • Manufacturer name and address • Catalog number and description • DMF # (attachment #) STOP

  22. H. Controls for finished dosage • Sampling procedure • Produced as multidose or aliquot in multiple vials • If multi-vials, sampling procedure to assure unbiased representation STOP

  23. H. Controls for finished dosage (contn) • Regulatory specs, procedures and testing schedules • Provide: • Test, acceptance criteria, procedure, and test schedule Each batch should meet these criteria during entire shelf life STOP

  24. H. Controls for finished dosage (contn) Regulatory specs (itemized) • Appearance • Radionuclide identity • Radiochemical identity • Radionuclide purity • Radiochemical purity • Radiochemical impurities • Assay (concentration) • Specific activity STOP

  25. H. Controls for finished dosage (contn) • pH • K222 concentration • Residue solvents • Chloro-deoxy glucose • Membrane filter integrity • Bacterial endotoxins • Sterility STOP

  26. I. Description of Analytical test procedures • For each (major) tests described, provide: • Test, STP #, Attachment #, Page number STOP

  27. J. Microbial validation • Includes procedures that ensure sterility • In manufacturing facility • Synthesis box and its components • Facility environmental controls • Clean room • Aseptic techniques • Final filtration • Finished product microbial testing STOP

  28. K. Stability and batch data • Expiration dating period • Stability data (a curve) • Post approval commitment • Annually, minimally one batch tested for the following tests • List these tests STOP

  29. L. Vials and outer label • Copies of proposed vial description and outer packaging and label • As an attachment STOP

  30. PET Center • Scanner • Cyclotron • Chemistry Laboratories • Radiopharmacy • Offices • Personnel STOP

  31. Scanner Several options, but does not necessarily affects our task at hand: • CTI-Siemens HR+ • GE Advance • CTI CT/PET • GE CT/PET • Philips PET and CT/PET STOP

  32. Cyclotron Is an important factor in preparing this document Several to choose from: • CTI RDS 111; 11 MeV • GE 10MeV or 18.5 MeV • IBA (various) • Others… STOP

  33. Medical Cyclotron Are deutrons as common and important? • Acceleration Capability • Particle • + v/s –ve ions • Single particle (Protons) v/s dual particles (proton & deuteron) • Energy • Nuclear Reaction • Target Material and Design STOP

  34. Isotope Production Issues may not be pertinent to FDG book, but would impact on what document we prepare • Small Medical Cyclotron (<15 MeV) • C-11 • N-13 • O-15 • F-18 • Large Cyclotron (>15 MeV) • Br-75, Br-76 • Ga-68 • I-122 STOP

  35. Cyclotron Target Yields These factors would influence the details for the document • Dependent on: 1. Nuclear Reaction 2. Target Design Physical (silver, tantalum, HP, LP, HV) STOP

  36. Radiochemistry Laboratories • Hot Cells • Fume Hoods • Laminar flow Hood • HPLC • GC • Synthesis Modules • Dose drawing station STOP

  37. Other Issues We may want to emphasize on radiation safety factor as guidance (FDA does not cover it) • Radiation Exposure from 1 mCi unshielded • General Nuclear Medicine clinic • 0.02 – 0.22 mR/h at 1 meter • PET clinic • 0.58 mR/h at 1 meter (5.8 R/h at 1 cm) • Patient handling STOP

  38. Return to Main Menu

More Related